EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...

A Scandinavian economic behemoth, Novo Nordisk is the highest valued company in Europe at over $500 billion, which exceeds ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Novo Nordisk A/S shares rose as surging sales of the blockbuster weight-loss treatment Wegovy reassured investors after rival ...

Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its ...

Novo Nordisk’s Wegovy helped people with a fatty liver disease called MASH experience improvements in liver scarring and achieve symptom resolution, new data show.

Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk, whose profits from blockbuster weight-loss ...